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Abstract
Background: Post-operative adhesions are an expected outcome with nearly every abdominal operation.
Adhesions are not always symptomatic, but when they are, they can cause a variety of problems. Small bowel
obstructions are a potential complication and are caused by abdominal adhesions in 75% of cases. This
complication would be one best avoided, and as a result numerous prophylactic agents have been developed in
hopes of decreasing the occurrence of adhesions.
Seprafilm Adhesion Barrier has been used since 1996 and has been largely effective in decreasing the
incidence and severity of abdominal adhesions. A thin sheet of Seprafilm placed in the abdominal cavity
before closure, keeps the organs from sticking to each other and forming scar tissue as the surgical site heals.
The purpose of this systematic review is to evaluate the available research and determine if Seprafilm reduces
the incidence of small bowel obstruction after laparotomy, as it does with adhesions.
Methods: An exhaustive search of medical literature was completed using Medline-OVID, CINAHL and
EBM Reviews Multifile. The keywords Seprafilm, Hyaluronic Acid, Carboxymethylcellulose, biocompatible
materials, artificial membranes, laparotomy, tissue adhesions and intestinal obstruction were used as search terms.
The search was limited to articles written in English with human subjects. Only randomized controlled trials
were included. Studies with pediatric subjects or gynecological surgeries were excluded.
Results: Three articles met the inclusion criteria and were incorporated in this review. Small bowel
obstruction as an outcome after laparotomy was explored as well as several study-specific outcomes. The trials
used Seprafilm in a randomized treatment group before closing the incision. Post-operative monitoring was
completed in order to screen for the incidence of small bowel obstruction between the treatment and control
groups. None of the studies found that the use of Seprafilm reduced the incidence of post-operative bowel
obstruction, although some positive findings were additionally presented.
Conclusion: Although Seprafilm has been proven to decrease the incidence and severity of abdominal
adhesions; the research available at this time does not show the same decreased incidence for post-operative
small bowel obstructions. Additional large-scale, randomized controlled trials would be beneficial to further
investigate this topic.
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Abstract   
Background: Post-operative adhesions are an expected outcome with nearly every 
abdominal operation.  Adhesions are not always symptomatic, but when they are, they 
can cause a variety of problems.  Small bowel obstructions are a potential complication 
and are caused by abdominal adhesions in 75% of cases.  This complication would be one 
best avoided, and as a result numerous prophylactic agents have been developed in hopes 
of decreasing the occurrence of adhesions.  
 
Seprafilm Adhesion Barrier has been used since 1996 and has been largely effective in 
decreasing the incidence and severity of abdominal adhesions.  A thin sheet of Seprafilm 
placed in the abdominal cavity before closure, keeps the organs from sticking to each 
other and forming scar tissue as the surgical site heals.  The purpose of this systematic 
review is to evaluate the available research and determine if Seprafilm reduces the 
incidence of small bowel obstruction after laparotomy, as it does with adhesions.    
 
Methods: An exhaustive search of medical literature was completed using Medline-
OVID, CINAHL and EBM Reviews Multifile.  The keywords Seprafilm, Hyaluronic 
Acid, Carboxymethylcellulose, biocompatible materials, artificial membranes, 
laparotomy, tissue adhesions and intestinal obstruction were used as search terms.  The 
search was limited to articles written in English with human subjects.  Only randomized 
controlled trials were included.  Studies with pediatric subjects or gynecological surgeries 
were excluded. 
 
Results: Three articles met the inclusion criteria and were incorporated in this review.  
Small bowel obstruction as an outcome after laparotomy was explored as well as several 
study-specific outcomes.  The trials used Seprafilm in a randomized treatment group 
before closing the incision.  Post-operative monitoring was completed in order to screen 
for the incidence of small bowel obstruction between the treatment and control groups.  
None of the studies found that the use of Seprafilm reduced the incidence of post-
operative bowel obstruction, although some positive findings were additionally 
presented.  
 
Conclusion: Although Seprafilm has been proven to decrease the incidence and severity 
of abdominal adhesions; the research available at this time does not show the same 
decreased incidence for post-operative small bowel obstructions.  Additional large-scale, 
randomized controlled trials would be beneficial to further investigate this topic.    
 
Keywords: Seprafilm, Hyaluronic Acid, Carboxymethylcellulose, biocompatible 
materials, artificial membranes, laparotomy, tissue adhesions, intestinal obstruction  
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The use of Seprafilm Adhesion Barrier in Adult Patients Undergoing 
Laparotomy to Reduce the Incidence of Post-Operative Small Bowel 
Obstruction 
 
BACKGROUND 
 
  Abdominal adhesions are a health concern of many individuals who have 
previously had surgery.  In fact, they are so common that postoperative adhesions are an 
expected outcome with nearly every abdominal operation.  Adhesions are not always 
symptomatic, but when they are, they can cause chronic abdominal pain and are known to 
cause problems with fertility.  Depending on the size and location, adhesions can also 
complicate further surgeries.  Additionally, small bowel obstructions are caused by 
abdominal adhesions approximately 75% of the time.1 Post-operative bowel obstruction 
is an immense complication for the patient to endure.  There is an increase in healthcare 
costs for the patient due to additional hospitalizations, potential for further complications 
and the possible need for subsequent surgery to treat the bowel obstruction.     
 For many years now, the healthcare field has been trying to identify possible 
prophylactic treatments which could decrease the incidence of abdominal adhesions post-
operatively.  In 1996, a study was published which found that the use of Seprafilm 
Adhesion Barrier was largely effective in decreasing the incidence, extent and severity of 
abdominal adhesions after surgery.2 Seprafilm is a bioresorbable membrane that is made 
of sodium hyaluronate and carboxymethylcellulose.  A thin sheet of film is placed over 
the organs in the abdominal cavity before the incision is closed.  Seprafilm keeps the 
organs from sticking to each other and from forming scar tissue as the surgical site heals.  
The film does not need to be removed, as it conveniently becomes a gel, is absorbed by 
the body and is excreted naturally within 28 days.3  
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 The safety of this product has been established, and research has shown the 
benefit of using Seprafilm to reduce the incidence of adhesions.  The purpose of this 
systematic review is to evaluate the available research and determine if Seprafilm reduces 
the incidence of small bowel obstruction after laparotomy, as it does with adhesions.    
METHODS 
 
 An exhaustive search of available medical literature was completed using 
Medline-OVID, CINAHL and Evidence-Based Medicine Reviews Multifile.  The 
keywords Seprafilm, Hyaluronic Acid, Carboxymethylcellulose, biocompatible materials, 
artificial membranes, laparotomy, tissue adhesions and intestinal obstruction were used 
as search terms.  The literature search was limited to articles written in the English 
language and with humans as the subject.  Studies that included pediatric subjects or 
gynecological surgeries were excluded.  A complete review of references was 
additionally performed, and a cited reference search was completed in the Web of 
Science database.  After assessing the potential full-text articles, it was determined that 
randomized controlled trials would be included in this systematic review and all other 
types of studies would be excluded.  Studies were not excluded based on date of 
publication.  
 The GRADE criteria was used to assess the validity and the quality of each 
article.  The studies were critically appraised and then placed into categories based on the 
strength of their evidence.  The categories used were high, medium, low and very low 
and this compiled data can be found in Table I.  
RESULTS  
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 A total of three articles4, 5, 7 that met the inclusion and exclusion criteria 
mentioned above were appraised in this systematic review.  Outcomes of small bowel 
obstruction (SBO) after open abdominal surgery were explored along with several 
additional outcomes specific to each study.  One study by Hayashi et al4 researched 
participants who were being treated for gastric cancer and would be undergoing 
gastrectomy.  The primary endpoint in this study was the incidence of bowel obstruction 
while secondary endpoints looked at morbidity and mortality both intraoperatively and 
postoperatively.  The second study, conducted by van der Wal et al,5 presented the 10-
year follow-up results from original research published in 2001 by Vrijland et al.6 This 
study monitored patients with sigmoid diverticulitis or obstructed rectosigmoid who 
would be having Hartmann’s procedure, a type of colorectal surgery.  The third study by 
Fazio et al7 published delayed results from research started by Beck et al.8 This report 
focused on a large population undergoing intestinal resection.  The research monitored 
the overall rate of SBO after surgery and the incidence of adhesive small bowel 
obstruction (ASBO), which required reoperation.      
Hayashi et al 
 Hayashi et al4 was a randomized controlled trial which took place in Japan.  Adult 
patients with gastric cancer who were scheduled to have gastrectomy were entered into 
the study between August 2003 and September 2006.  A total of 150 patients were 
enrolled into the study.  Subjects were excluded if they were older than 80 years of age, 
pregnant, had a past history of small bowel obstruction, ascites, metastasis or liver or 
renal dysfunction.  Patients who ended up having laparascopic surgery, a transverse 
incision or peritoneal carcinomatosis were also excluded.  Written informed consent was 
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obtained and subjects were randomized into the Seprafilm treatment group or the control 
group using the minimization technique.  Prognostic differences were present between 
groups with the amount of experience of the surgeons differing and the individual 
procedures being performed were not equal.  The patients in the control group were also 
in surgery for a longer duration and the estimated blood loss was greater in the control 
group than in the treatment group.  The Seprafilm group consisted of 70 participants and 
the control group totaled 74 people after six subjects were excluded.  The patients were 
blinded to their assigned group and study evaluators were also blinded to whether or not 
Seprafilm had been used.4 
  Various surgeries which required an upper midline abdominal incision were 
performed.  Those in the Seprafilm treatment group received two sheets of Seprafilm 
between the fascia of the abdomen and the surface of the small intestines before closure.  
It was not revealed in the operative report if Seprafilm had been used.4   
 Patients were followed post-operatively to measure the incidence of SBO, which 
was identified by clinical symptoms, physical examination, radiographs, or a combination 
of such.  If small bowel dilatation was seen on abdominal x-ray or CT, patients received a 
nasoenteric tube for up to five days.  Those who did not show signs of improvement 
underwent an additional surgery for post-operative SBO.   
 SBO occurred in four patients in the Seprafilm group and in seven patients in the 
control group.  None of the SBO patients in the Seprafilm group required surgery but one 
patient in the control group required reoperation for SBO that did not resolve with the 
placement of the nasoenteric tube.  A second patient in the control group had two 
separate episodes of SBO during follow-up, although it was managed non-surgically. 
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 The results of this study were not statistically significant and confidence intervals 
were not discussed.  The Seprafilm group experienced SBO at a rate of 5.7% while the 
control group incidence was 9.5% (P= 0.534).  The cumulative incidence of SBO was 
lower in the Seprafilm group throughout the follow-up period, but was not found to be 
significant with a P-value of 0.378.4   
van der Wal et al 
 The report by van der Wal et al5 discussed long-term results from a study which 
began ten years prior.  The original single-blinded study, which was conducted between 
1996 and 1998 and published by Vrijland et al,6 researched patients who were scheduled 
for the two-part Hartmann’s procedure for sigmoid diverticulitis or an obstructed 
rectosigmoid.  There were eight hospitals in the Netherlands that participated and initially 
71 patients enrolled, but only 42 could be evaluated. The patients were randomized into 
the Seprafilm treatment group or control group at the time of surgery.  The treatment and 
control groups were not equal with respect to prognostic factors.  There were patients in 
the treatment group who had the peritoneum sutured, while no suturing of the peritoneum 
occurred in the control group.  Also, there were more patients in the Seprafilm group with 
adhesions present at the time of the first surgery than in the control group.6 
 Randomization was obtained by a computer-generated list and then sealed 
envelopes were opened in surgery to direct the surgeon to either use Seprafilm before 
closure or not.6 During the first surgery, Seprafilm was placed under the midline incision 
and in the pelvic cavity just before the laparotomy wound was closed.  A mean of 1.9 
units of Seprafilm was used under the incision and a mean of 1.3 units was used in the 
pelvis.5 The second-stage surgery was done laparascopically and at this time, the midline 
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incision was visualized and the incidence and severity of developing adhesions was 
evaluated in all 42 subjects.  The initial results of this study were published in 2002 and 
reported that there were significantly less severe adhesions present at the time of the 
laparascopic procedure in the Seprafilm group when compared to the control group.5, 6 
 The results of the van der Wal5 study, published in 2011, are more applicable to 
this systematic review as the primary goal was to determine the long-term effects of 
Seprafilm in reducing SBO and chronic abdominal pain after surgery.  In order to follow-
up with the 42 patients who completed the two-part Hartmann’s procedure nearly ten 
years earlier, researchers contacted the medical providers of the enrolled patients and 
asked them to complete a questionnaire about their patient and also indicate if the patient 
was deceased.  Of the original 42 patients from the study, seven were lost to follow-up 
with 35 remaining for evaluation.   Of the original sample size, 83% were still available 
for follow-up, 16 in the Seprafilm treatment group and 19 in the control group.  The 
patients that were willing and able to do so were also given some questionnaires to 
complete.  The information from the questionnaires, along with reviewed hospital and 
medical records, provided data that were helpful in determining the number of post-
operative SBO and abdominal pain complaints after surgery.5 
 Hospital records showed that there were two readmissions for post-operative SBO 
in the control group during the follow-up period and none in the Seprafilm group.  
Although there were fewer incidences of SBO in the treatment group, this finding was 
not statistically significant.  There were results of significance that were found when 
analyzing the patient questionnaires.  The patients in the Seprafilm group reported 
significantly fewer abdominal complaints, defined as pain, nausea and obstipation, when 
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compared to the control group: “6 patients (35%) in the Seprafilm group experienced at 
least 1 episode of abdominal complaints of 3 months or longer, whereas 14 patients 
(78%) in the control group went through at least 1 episode of abdominal complaints of 3 
months or longer (P = 0.018).”5 
Fazio et al 
 Fazio et al7 was a prospective, randomized, controlled study that involved 83 
surgeons from 22 centers throughout the United States, Europe and Canada.  Patients 
entered into the study between June 1998 and November 2000 (for the complete details 
of this study’s methodology, the original article published by Beck et al8 was reviewed). 
Subjects who were eligible to participate were adults under 85 years of age who were 
going to have a surgery for colorectal resection.  Patients having lysis of adhesions for 
SBO were initially included in the sample population, but were ultimately removed, 
evaluated in a separate group and not included in the results.  Exclusion criteria included 
pregnancy, patients with active cancer or cancer within five years of enrollment in the 
study, those undergoing laparoscopic surgery, patients with abdominal trauma, intra-
abdominal infection, history of severe allergy, history of pulmonary embolism or deep 
vein thrombosis within one year of surgery and patients with any other medical condition 
for which they were not expected to survive at least five years.7, 8 
 There were 1701 patients who met the eligibility criteria and were scheduled to 
have open resection of the small intestines, colon or rectum.  Written consent was 
obtained from the patients at least 30 days prior to surgery.  As surgery was completed, 
just before the abdomen was closed, the patients were randomized into the Seprafilm 
treatment group or the non-treatment control group.  Randomization was performed “with 
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a table of random numbers…used to balance the distribution of patients scheduled for 
two-stage surgical procedures across treatment groups and participating surgeons.”7 
There were prognostic differences between groups as the control group consisted of 
sicker patients with history of diabetes and deep vein thrombosis.  There were also fewer 
patients in the treatment group that received perioperative steroids when compared to the 
control group.  This was a patient-blinded study as the patients were not aware to which 
group they were assigned, but the information was available to the surgeons and 
researchers.7 
 The Seprafilm treatment group consisted of 840 patients and there were 861 
patients in the control group.  Surgeons who placed the Seprafilm before abdominal 
closure applied three to ten sheets to the surfaces of abdominal organs and tissue that had 
been manipulated and was thought to be adhesiogenic.  Patients who had a future 
procedure as a two-part surgery were given an additional sheet of Seprafilm at the time of 
the subsequent surgery.  The patients in the Seprafilm group received a mean of 4.4 
sheets while those in the control group did not receive Seprafilm or a placebo.7, 8 
 The paper presented by Beck et al8 in 2003 was focused on the safety results of 
Seprafilm.  Fazio et al7 published the results for the incidence and severity of SBO in 
2006 after an extended follow-up period with a mean of 3.5 years.  To maintain the SBO 
data, clinical personnel followed-up with the patients by telephone at set intervals.  
Hospital and surgical records were also reviewed after hospitalization in order to evaluate 
for potential bowel obstruction.  Post-operative patients with suspected bowel 
obstructions were classified into three categories:   
Class Ia consisted of adhesive or nonadhesive bowel obstruction confirmed by 
surgery or autopsy…Class Ib included bowel obstruction confirmed by contrast 
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enhanced CT scan or small bowel follow-through with oral contrast.  Class II was 
defined by the presence of clinical symptoms (at least 3 of the following: nausea, 
vomiting, abdominal pain, abdominal distention, or the absence of stool or flatus 
in the previous 24 hours) in addition to documented suspected or confirmed bowel 
obstruction in the medical record and a plain x-ray or CT scan showing or failing 
to rule out bowel obstruction, with an onset of 11 days or more after initial 
surgery.  This time interval was chosen to minimize the number of patients with 
prolonged ileus in this category.7       
 
 There were no significant differences between classes and the total number of 
patients in each of the three classes were similar in the treatment and control groups.  
Furthermore, Fazio et al7 found that there was no difference in the incidence of first post-
operative bowel obstruction when all three categories were combined.  The treatment and 
control groups each had an incidence of 12%.  The number of SBO caused by adhesions 
that required surgery were lower than anticipated.  However, during an analysis of the 
subgroups, statistically significant results were found in subgroup Ia showing that the 
Seprafilm treatment group suffered fewer SBO caused by adhesions.  The Seprafilm 
group was affected at a rate of 1.8% while 3.4% of the control group experienced ASBO 
post-operatively.  These results were statistically significant with a P-value of less than 
0.05 and a confidence interval of 95% (see Table II).  It was concluded that the use of 
Seprafilm provided a reduction in the risk of developing ASBO post-surgically and the 
Seprafilm was determined to be the only variable that predicted this outcome.7          
DISCUSSION 
  
 Although prior research2 has proven that Seprafilm Adhesion Barrier reduces the 
incidence of post-operative abdominal adhesions, this systematic review did not reach the 
same conclusion when reviewing the outcome of post-operative small bowel 
obstructions.  These three studies4, 5, 7 did not produce statistically significant results that 
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the use of Seprafilm decreases the incidence of SBO as it does adhesions.  Still, the 
studies identified some benefits to using Seprafilm, some with statistically significant 
findings and others without (see Table II).  Abdominal adhesions and subsequent SBO 
after laparotomy is a prevalent problem in medicine which often leads to additional 
hospitalizations, potential for more surgery, further complications and increased health 
care costs.  Finding a safe and effective prophylactic treatment to decrease the incidence 
of SBO would be very useful and beneficial to many different types of surgical patients.  
 As suggested by van der Wal et al,5 there is benefit to performing a study with a 
long follow-up period when investigating the incidence of SBO after the use of a product 
like Seprafilm.  This lengthy follow-up is important, because SBO are not always an 
immediate complication after surgery; they can take many years to become apparent.  It 
would be of great utility to have a large, well-done, randomized controlled trial 
completed in the future with this specific long-term endpoint in order to better understand 
what benefit post-surgical patients can expect from Seprafilm.  
 The three studies4, 5, 7 that are analyzed in this systematic review were all 
randomized controlled trials, so by default they began as high quality evidence according 
to the GRADE criteria.9 Each study was composed of a Seprafilm treatment group and a 
control group.  The process of randomizing was discussed in detail more in the van der 
Wal5 article than in the other two studies.  Hayashi et al4 did not describe their 
randomization process by minimization, which suggests that it may have not been well 
randomized.  Fazio et al7 stated that patients were randomized, but this did not happen 
until the end of surgery.  The subjects remained in their assigned groups through the 
remainder of the trials and no crossover occurred between groups.   
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 Additionally, all studies were blinded in some fashion. All articles4, 5, 7 stated that 
patients remained blinded to their assigned group, but the surgeons were not blinded.  
Only Hayashi et al4 additionally mentioned that the researchers, as well as the patients, 
were blinded.   
 Each article claimed that prognostic factors were equal between the treatment and 
control groups, but upon further analysis it seems that unequal prognostic factors with no 
statistical adjustment could have led to inconsistency among results.  For example, 
Hayashi et al4 stated that characteristics between both groups were equal, but failed to 
mention that the experience of the surgeons differed and the procedures performed in 
each group were not equal.  The patients in the control group appear to have been sicker, 
and therefore the treatment effect could have been underestimated when compared to the 
results of the control.  Vrijland et al6 stated that groups were equal with respect to 
preoperative data, medical history and preoperative physical exam, although, based on 
prognostic data included in their tables, it seems that there were some differences.  These 
differences may have distorted the results.  There were patients in the treatment group 
who had the peritoneum sutured, while no suturing of the peritoneum occurred in the 
control group.  Sutures are known to be a common cause for adhesion formation and this 
variable should have been included in their discussion of the results, as it could be an 
important factor leading to skewed results.  Also, there were more patients in the 
Seprafilm group with adhesions present at the time of the first surgery than in the control 
group.  Prognostic factors between the treatment and control groups in Fazio et al7 also 
appear to be unequal, although this was not discussed in their paper.  The control group 
consisted of more patients with history of diabetes and history of deep vein thrombosis.  
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Fewer patients in the treatment group received perioperative steroids when compared to 
the control group.  Had the treatment group received equal amounts of steroids during the 
procedure, it is possible that the incidence of SBO would have, in turn, produced 
statistically significant results. 
 One additional limitation in the van der Wal et al5 study was the use of subjective 
data through questionnaires to determine some of the long-term outcomes being 
researched in the article.  It is difficult to compare this data to other studies that used 
more scientific methods for identifying abdominal pathology.  It is evident that pain to 
one person may be described as simply an ache to someone else.  Therefore, although 
their long-term follow-up period was helpful in some aspects, the way in which it was 
conducted made it susceptible to bias and some of their results cannot be used for 
comparison in the future.  
 Another example of inconsistency in each of these three studies4, 5, 7 is due to the 
differing number of sheets of Seprafilm used between studies and between patients within 
each study group.  Surgeons in the Fazio et al7 study placed between three and ten sheets 
of Seprafilm for patients in the treatment group.  Hayashi et al4 used a pre-determined 
number with all patients in the treatment group receiving two sheets of Seprafilm.  Lastly, 
van der Wal et al5 did not discuss the exact number of Seprafilm sheets used in the 
treatment group, but reported the mean quantity of units applied under the midline 
incision as 1.9 sheets and 1.3 sheets in the pelvis.  None of the studies gave an 
explanation or reasoning for the differing amounts of Seprafilm used, but it is possible 
that patients who received more Seprafilm healed better and with fewer complications.   
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 Indirectness was not a problematic issue in the studies4, 5, 7 used for this systematic 
review.  The questions being researched in these papers were the same as the outcomes 
and patient important outcomes were evaluated.  Precision, however, was lacking.  The 
sample size in the van der Wal5 study was very low with 42 patients total.  The number of 
participants was large in Fazio et al7 with the study following 1701 people and there was 
an adequate sample size in Hayashi et al4 with 144 subjects.  Only the Fazio et al7 and 
van der Wal et al5 studies included 95% confidence intervals; Hayashi et al4 did not 
discuss confidence intervals throughout their paper.  None of the P-values were less than 
0.05 for the primary outcomes in these studies, meaning that the results were not 
statistically significant.  Table II summarizes which other P-values were significant 
among these three trials.4, 5, 7  
 There was potential for publication bias from the Fazio et al7 study.  This research 
was supported by a grant from the manufacturer of Seprafilm, the Genzyme Corporation.  
Additionally, a number of the same authors have overlapped and have helped to publish 
many of the articles currently available on Seprafilm and its utility in decreasing post-
operative adhesions and SBO.    
 All studies4, 5, 7 used in this systematic review were critically appraised and the 
quality of evidence was assessed using the GRADE criteria.9 For all of the shortcomings 
discussed above pertaining to blinding, precision, inconsistency, lack of similar 
prognostic factors and publication bias, the quality of evidence of these articles was 
adjusted from high to either low or very low (see Table I).  Results from future research 
would be very likely to have an important impact on the continued use of Seprafilm and 
the confidence with which surgeons recommend its use to their patients.   
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CONCLUSION 
 Although Seprafilm has been proven to decrease the incidence and severity of 
abdominal adhesions, the research available at this time does not show the same 
decreased incidence for post-operative small bowel obstructions.  Seprafilm has shown 
other benefits for the surgical patient such as decreased post-operative abdominal 
complaints and fewer re-operations required for adhesive small bowel obstructions.  
Additional large-scale, randomized controlled trials with similar prognostic factors 
between groups and long-term follow-up will be needed to further investigate the 
potential benefit of using Seprafilm for laparotomy patients to reduce the incidence of 
small bowel obstruction. 
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Table I: Characteristics of Reviewed Studies 
 
Table I: Characteristics and Quality of Randomized Controlled Trials Using Seprafilm to Reduce the Incidence of Post-
Operative Small Bowel Obstruction 
 
Author Study 
type 
Randomization Blinding Limitations Publication 
Bias 
Inconsistency Similar 
prognostic 
factors 
Precision 
(CI, P-
values) 
GRADE 
                    
Hayashi et 
al4 
RCT Randomization 
using 
minimization 
technique 
Patients 
and 
evaluators 
blinded 
Minimization 
technique not 
described; 
Confounders 
underestimated 
the treatment 
effect 
No 2 sheets 
Seprafilm 
Not 
adequate 
No CI; no 
significant P-
values 
Very 
low  
 
van der Wal 
et al5 
RCT Computer-
generated 
randomization 
and sealed 
envelopes used 
Patient 
blinded 
Small sample 
size; lack of 
blinding of 
evaluators; 
some outcomes 
measured 
subjectively 
No Mean 1.9 
units 
Seprafilm 
abdominal; 
1.3 units 
pelvic 
Not 
adequate 
95% CI; P-
value 0.018 
for 
significantly 
lower 
chronic 
abdominal 
complaints 
in treatment 
group 
Low 
 
Fazio et al7 RCT Randomization 
with random 
number assigned 
by table 
Patient 
blinded 
Lack of 
blinding of 
researchers 
Potentially 3-10 sheets 
Seprafilm at 
1st procedure 
and additional 
sheet at 2nd 
procedure 
Not 
adequate 
95% CI; P- 
value < 0.05 
incidence of 
reoperation 
for ASBO in 
treatment 
group 
Low 
 
 
 
    Downgraded 3 levels for lack of explanation of randomization, differences between prognostic factors and lack of confidence intervals and significant P-values. 
    Downgraded 2 levels for small sample size and differences between prognostic factors.  
    Downgraded 2 levels for potential publication bias and differences between prognostic factors. 
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Table II: Summary of Findings 
 
 
Table II: Summary of Findings 
 
Author 
# in 
treatment 
group 
# in control 
group 
Length of 
follow-up 
# Lost to 
follow-up Statistics  
Significant 
P-values 
1. Seprafilm reduced 
incidence of SBO? 
2. Secondary results 
        
Hayashi et al4 70 74 
28 months 
treatment 
group, 27 
months 
control group 
0 
RR: 0.6 
RRR: 0.4 
ARR: 0.038 
NNT: 27 
 
None 
1. No 
2. Cumulative incidence 
of SBO was slightly 
lower in treatment 
group  
van der Wal et 
al5 16 19 
median 126 
months 
treatment 
group, 128 
months 
control group 
7 out of 42 
RR: 0 
RRR: 1 
ARR: 0.105 
NNT: 10 
 
P = 0.018 
incidence 
of chronic 
abdominal 
complaints 
1. No 
2. Significantly fewer 
chronic abdominal 
complaints in 
treatment group; no 
subjects in treatment 
group were readmitted 
due to SBO 
Fazio et al7 840 861 mean 3.5 years 0 
RR: 0.53 
RRR: 0.47 
ARR: 0.016 
NNT: 63  
 
P < 0.05 
incidence 
of 
reoperation 
for ASBO 
1. No 
2. Significantly fewer 
patients in treatment 
group requiring 
reoperation for 
ASBO. 
 
 according to P-values, results are not statistically significant 
 statistics measured secondary outcome of incidence of ASBO. Primary outcome with RR= 1 
 statistics measured overall incidence of SBO 
 statistics measured occurrence of readmission due to SBO 
 
 
 
